Literature DB >> 21571497

[Follow-up of tetralogy of Fallot after repair].

Isabelle Van Aerschot1, Laurence Iserin.   

Abstract

Repair of tetralogy of Fallot (TOF) exists for more than 40 years. This repair results in a pulmonary regurgitation, which is usually well tolerated for two decades or so, but eventually this is injurious for the right ventricle (RV). The RV enlargement and severe RV dysfunction increase risk for ventricular tachycardia (VT) and sudden death in the long-term. The pulmonary valve replacement (PVR) is shifting earlier to preserve RV function before patients develop symptoms. Several parameters have to be considered to facilate correct timing for PVR (surgically of by catheterization) : echocardiography, magnetic resonance imaging, electrocardiogram and cardiopulmonary exercise. All patients should have regular follow-up in a specialized grown-up congenital heart disease (GUCH) center to detect as soon as possible pathological signs of RV enlargement. Implantable cardioverter-defibrillator (ICD) implantation for primary prevention and programmed ventricular stimulation in repaired TOF remain controversal.
Copyright © 2011 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21571497     DOI: 10.1016/j.lpm.2011.02.030

Source DB:  PubMed          Journal:  Presse Med        ISSN: 0755-4982            Impact factor:   1.228


  2 in total

1.  Surgical Treatment Outcomes of Tetralogy of Fallot: Experience of the Cardiovascular Department of the Mohammed VI University Hospital in Marrakech.

Authors:  Ahmed Salah Tandia; Marwan El Qady; Saloua El Karimi; Driss Boumzebra
Journal:  Cureus       Date:  2022-05-06

2.  Application of Real-Time Three-Dimensional Echocardiography to Evaluate the Pre- and Postoperative Right Ventricular Systolic Function of Patients with Tetralogy of Fallot.

Authors:  Cunying Cui; Lin Liu; Taibing Fan; Bangtian Peng; Zhaoyun Cheng; Zhenwei Ge; Yanan Li; Yuanyuan Liu; Yanwei Zhang; Feng Ai; Lianzhong Zhang
Journal:  Acta Cardiol Sin       Date:  2015-07       Impact factor: 2.672

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.